- Home
- Publications
- Publication Search
- Publication Details
Title
The war on cancer: are we winning?
Authors
Keywords
War on cancer, Targeted therapy, Biomarker, Cancer, Tumor marker, Predictive marker
Journal
TUMOR BIOLOGY
Volume 34, Issue 3, Pages 1275-1284
Publisher
Springer Nature
Online
2013-04-08
DOI
10.1007/s13277-013-0759-2
References
Ask authors/readers for more resources
Related references
Note: Only part of the references are listed.- Monitoring chronic lymphocytic leukemia progression by whole genome sequencing reveals heterogeneous clonal evolution patterns
- (2012) A. Schuh et al. BLOOD
- The Growing Arsenal of ATP-Competitive and Allosteric Inhibitors of BCR-ABL
- (2012) O. Hantschel et al. CANCER RESEARCH
- Current approaches and future directions in the treatment of HER2-positive breast cancer
- (2012) Sara A. Hurvitz et al. CANCER TREATMENT REVIEWS
- Mutational Processes Molding the Genomes of 21 Breast Cancers
- (2012) Serena Nik-Zainal et al. CELL
- New Strategies in Melanoma: Molecular Testing in Advanced Disease
- (2012) Scott E. Woodman et al. CLINICAL CANCER RESEARCH
- Anti-metastatic Treatment in Colorectal Cancer: Targeting Signaling Pathways
- (2012) Clara Lemos et al. CURRENT PHARMACEUTICAL DESIGN
- Randomized Controlled Trials and Comparative Effectiveness Research
- (2012) Olwen M. Hahn et al. JOURNAL OF CLINICAL ONCOLOGY
- Timing of Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitor Therapy in Patients With Lung Cancer WithEGFRMutations
- (2012) Teresa Moran et al. JOURNAL OF CLINICAL ONCOLOGY
- Epidermal Growth Factor Receptor (EGFR) Signaling and Covalent EGFR Inhibition in Lung Cancer
- (2012) Johannes M. Heuckmann et al. JOURNAL OF CLINICAL ONCOLOGY
- Lapatinib with trastuzumab for HER2-positive early breast cancer (NeoALTTO): a randomised, open-label, multicentre, phase 3 trial
- (2012) José Baselga et al. LANCET
- Dabrafenib in BRAF-mutated metastatic melanoma: a multicentre, open-label, phase 3 randomised controlled trial
- (2012) Axel Hauschild et al. LANCET
- Lapatinib versus trastuzumab in combination with neoadjuvant anthracycline-taxane-based chemotherapy (GeparQuinto, GBG 44): a randomised phase 3 trial
- (2012) Michael Untch et al. LANCET ONCOLOGY
- Tumor Markers in Clinical Practice: A Review Focusing on Common Solid Cancers
- (2012) Michael J. Duffy MEDICAL PRINCIPLES AND PRACTICE
- It's About Time: Lessons for Solid Tumors from Chronic Myelogenous Leukemia Therapy
- (2012) J. R. Westin et al. MOLECULAR CANCER THERAPEUTICS
- Omics and therapy - A basis for precision medicine
- (2012) Joseph P. Garay et al. Molecular Oncology
- Cetuximab-mediated Tumor Regression Depends on Innate and Adaptive Immune Responses
- (2012) Xuanming Yang et al. MOLECULAR THERAPY
- Sequence analysis of mutations and translocations across breast cancer subtypes
- (2012) Shantanu Banerji et al. NATURE
- Clonal evolution in cancer
- (2012) Mel Greaves et al. NATURE
- Comprehensive molecular portraits of human breast tumours
- (2012) Daniel C. Koboldt et al. NATURE
- Genomic landscape of liver cancer
- (2012) Zemin Zhang NATURE GENETICS
- Integrative genome analyses identify key somatic driver mutations of small-cell lung cancer
- (2012) Martin Peifer et al. NATURE GENETICS
- Survival in BRAF V600–Mutant Advanced Melanoma Treated with Vemurafenib
- (2012) Jeffrey A. Sosman et al. NEW ENGLAND JOURNAL OF MEDICINE
- Trastuzumab Emtansine for HER2-Positive Advanced Breast Cancer
- (2012) Sunil Verma et al. NEW ENGLAND JOURNAL OF MEDICINE
- Intratumor Heterogeneity and Branched Evolution Revealed by Multiregion Sequencing
- (2012) Marco Gerlinger et al. NEW ENGLAND JOURNAL OF MEDICINE
- Reducing death from cancer: what will it take?
- (2012) Margaret L. Kripke TUMOR BIOLOGY
- Circumventing Cancer Drug Resistance in the Era of Personalized Medicine
- (2012) Levi A. Garraway et al. Cancer Discovery
- Dual HER2-targeted approaches in HER2-positive breast cancer
- (2011) Eugene R. Ahn et al. BREAST CANCER RESEARCH AND TREATMENT
- Many Tumors in One: A Daunting Therapeutic Prospect
- (2011) Chibawanye I. Ene et al. CANCER CELL
- Mosaic Amplification of Multiple Receptor Tyrosine Kinase Genes in Glioblastoma
- (2011) Matija Snuderl et al. CANCER CELL
- EGFR-mutated oncogene-addicted non-small cell lung cancer: Current trends and future prospects
- (2011) Jean-Charles Soria et al. CANCER TREATMENT REVIEWS
- Does anti-EGFR therapy improve outcome in advanced colorectal cancer? A systematic review and meta-analysis
- (2011) Claire L. Vale et al. CANCER TREATMENT REVIEWS
- New Strategies in HER2-Overexpressing Breast Cancer: Many Combinations of Targeted Drugs Available
- (2011) V. Abramson et al. CLINICAL CANCER RESEARCH
- A systematic review and meta-analysis of KRAS status as the determinant of response to anti-EGFR antibodies and the impact of partner chemotherapy in metastatic colorectal cancer
- (2011) Barbara-Ann Adelstein et al. EUROPEAN JOURNAL OF CANCER
- Concerns About Provenge Simmer as CMS Ponders Coverage
- (2011) M. Goozner JNCI-Journal of the National Cancer Institute
- Delivering affordable cancer care in high-income countries
- (2011) Richard Sullivan et al. LANCET ONCOLOGY
- Effect of crizotinib on overall survival in patients with advanced non-small-cell lung cancer harbouring ALK gene rearrangement: a retrospective analysis
- (2011) Alice T Shaw et al. LANCET ONCOLOGY
- A continuum model for tumour suppression
- (2011) Alice H. Berger et al. NATURE
- Despite steep costs, payments for new cancer drugs make economic sense
- (2011) Frank R Lichtenberg NATURE MEDICINE
- Improved Survival with Vemurafenib in Melanoma with BRAF V600E Mutation
- (2011) Paul B. Chapman et al. NEW ENGLAND JOURNAL OF MEDICINE
- Pertuzumab plus Trastuzumab plus Docetaxel for Metastatic Breast Cancer
- (2011) José Baselga et al. NEW ENGLAND JOURNAL OF MEDICINE
- Trastuzumab in the Adjuvant Treatment of HER2-Positive Early Breast Cancer Patients: A Meta-Analysis of Published Randomized Controlled Trials
- (2011) Wenjin Yin et al. PLoS One
- Exploring the Genomes of Cancer Cells: Progress and Promise
- (2011) M. R. Stratton SCIENCE
- The efficacy of HER2-targeted agents in metastatic breast cancer: a meta-analysis
- (2010) C. A. Harris et al. ANNALS OF ONCOLOGY
- Perspective on updated treatment guidelines for patients with gastrointestinal stromal tumors
- (2010) Jean-Yves Blay et al. CANCER
- Towards global consensus in the treatment of gastrointestinal stromal tumor
- (2010) Peter Reichardt et al. Expert Review of Anticancer Therapy
- Trastuzumab in combination with chemotherapy versus chemotherapy alone for treatment of HER2-positive advanced gastric or gastro-oesophageal junction cancer (ToGA): a phase 3, open-label, randomised controlled trial
- (2010) Yung-Jue Bang et al. LANCET
- Distant metastasis occurs late during the genetic evolution of pancreatic cancer
- (2010) Shinichi Yachida et al. NATURE
- Anaplastic Lymphoma Kinase Inhibition in Non–Small-Cell Lung Cancer
- (2010) Eunice L. Kwak et al. NEW ENGLAND JOURNAL OF MEDICINE
- Inhibition of Mutated, Activated BRAF in Metastatic Melanoma
- (2010) Keith T. Flaherty et al. NEW ENGLAND JOURNAL OF MEDICINE
- Sipuleucel-T Immunotherapy for Castration-Resistant Prostate Cancer
- (2010) Philip W. Kantoff et al. NEW ENGLAND JOURNAL OF MEDICINE
- Cancer Statistics, 2009
- (2009) A. Jemal et al. CA-A CANCER JOURNAL FOR CLINICIANS
- Prognosis of Women With Metastatic Breast Cancer byHER2Status and Trastuzumab Treatment: An Institutional-Based Review
- (2009) Shaheenah Dawood et al. JOURNAL OF CLINICAL ONCOLOGY
- How Much Is Life Worth: Cetuximab, Non-Small Cell Lung Cancer, and the $440 Billion Question
- (2009) T. Fojo et al. JNCI-Journal of the National Cancer Institute
- Use of Archived Specimens in Evaluation of Prognostic and Predictive Biomarkers
- (2009) R. M. Simon et al. JNCI-Journal of the National Cancer Institute
- The cancer genome
- (2009) Michael R. Stratton et al. NATURE
- Oncogene Addiction
- (2008) I. B. Weinstein et al. CANCER RESEARCH
Find Funding. Review Successful Grants.
Explore over 25,000 new funding opportunities and over 6,000,000 successful grants.
ExploreAsk a Question. Answer a Question.
Quickly pose questions to the entire community. Debate answers and get clarity on the most important issues facing researchers.
Get Started